Mai Knut, Fassnacht Martin, Führer-Sakel Dagmar, Honegger Jürgen B, Weber Matthias M, Kroiss Matthias
Dtsch Arztebl Int. 2021 Jun 11;118(Forthcoming):389-96. doi: 10.3238/arztebl.m2021.0143.
The immunologically mediated side effects of immune checkpoint inhibitors (CPI) often involve the endocrine system as well, and they can even be fatal, as in the case of unrecognized hypophysitis. Distinguishing such side effects from tumor-related changes is often difficult, because their clinical features can be nonspecific.
This review is based on publications retrieved by a selective search in PubMed, with special attention to international recommendations.
Depending on their target molecules, the CPI now in use differ from one another in the incidence of side effects such as autoimmune thyroid disease (4-16%), hypophysitis (0.1- 18%), adrenalitis (0.7-8%), and autoimmune diabetes mellitus (0.5-2%). The typical clinical warning signs and laboratory constellations of hypophysitis include exhaustion, hyponatremia, and headache. Hypo- and hyperthyroidism and primary adrenocortical insufficiency likewise have nonspecific manifestations. Autoimmune diabetes mellitus often takes a fulminant course. Patients being treated with CPI should be monitored at close intervals, at least as frequently as the administration of the drug, so that endocrine side effects can be recognized in time. In case of doubt, glucocorticoid supplementation should be given whenever hypocortisolism is suspected, even before endocrine evaluation is completed and the results are available. Interrupting or discontinuing CPI treatment is rarely indicated.
With the increasing number of patients being treated with CPI, more and more physicians from a wide variety of specialties, not necessarily working in specialized centers, now have to consider immunologically mediated endocrine side effects in the differential diagnosis, and treat them properly when they arise. These things should be done in collaboration with endocrinologists. The ongoing study of such side effects of the CPI now in use, and of those that will be introduced in the future, is important and will lead to improved understanding.
免疫检查点抑制剂(CPI)的免疫介导副作用通常也累及内分泌系统,甚至可能致命,如未被识别的垂体炎。将此类副作用与肿瘤相关变化区分开来往往很困难,因为其临床特征可能不具有特异性。
本综述基于在PubMed中进行选择性检索获得的文献,并特别关注国际推荐。
根据其靶分子不同,目前使用的CPI在自身免疫性甲状腺疾病(4 - 16%)、垂体炎(0.1 - 18%)、肾上腺炎(0.7 - 8%)和自身免疫性糖尿病(0.5 - 2%)等副作用的发生率上存在差异。垂体炎的典型临床警示信号和实验室指标包括乏力、低钠血症和头痛。甲状腺功能减退和亢进以及原发性肾上腺皮质功能不全同样具有非特异性表现。自身免疫性糖尿病通常呈暴发性病程。接受CPI治疗的患者应密切监测,至少与给药频率相同,以便能及时识别内分泌副作用。如有疑问,无论内分泌评估是否完成及结果如何,只要怀疑有皮质醇减少症,就应给予糖皮质激素补充。很少需要中断或停止CPI治疗。
随着接受CPI治疗的患者数量不断增加,越来越多来自各种专科的医生(不一定在专科中心工作)现在必须在鉴别诊断中考虑免疫介导的内分泌副作用,并在副作用出现时进行恰当治疗。这些工作应与内分泌科医生合作完成。对目前使用的CPI以及未来将推出的CPI的此类副作用进行持续研究很重要,这将有助于增进理解。